Fmr LLC Boosts Holdings in FibroGen, Inc. (NASDAQ:FGEN)

Fmr LLC increased its holdings in shares of FibroGen, Inc. (NASDAQ:FGEN) by 21.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 383,258 shares of the biopharmaceutical company’s stock after purchasing an additional 68,569 shares during the quarter. Fmr LLC owned 0.38% of FibroGen worth $153,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently made changes to their positions in FGEN. Point72 DIFC Ltd raised its stake in shares of FibroGen by 734.2% in the second quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 45,990 shares during the period. Doheny Asset Management CA purchased a new position in FibroGen during the 2nd quarter valued at approximately $48,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in FibroGen in the second quarter worth $130,000. Sei Investments Co. lifted its holdings in shares of FibroGen by 38.4% in the 2nd quarter. Sei Investments Co. now owns 149,342 shares of the biopharmaceutical company’s stock valued at $133,000 after acquiring an additional 41,442 shares during the last quarter. Finally, Squarepoint Ops LLC bought a new position in shares of FibroGen during the 2nd quarter valued at approximately $145,000. 72.71% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. StockNews.com initiated coverage on FibroGen in a research note on Monday, December 16th. They set a “hold” rating on the stock. William Blair reiterated a “market perform” rating on shares of FibroGen in a research note on Wednesday, November 13th. Finally, HC Wainwright upgraded shares of FibroGen to a “strong-buy” rating in a research note on Tuesday, December 17th.

FibroGen Stock Up 13.1 %

Shares of NASDAQ:FGEN opened at $0.40 on Monday. FibroGen, Inc. has a 52-week low of $0.18 and a 52-week high of $2.93. The business has a 50-day moving average price of $0.35 and a 200-day moving average price of $0.56. The stock has a market cap of $40.31 million, a price-to-earnings ratio of -0.33 and a beta of 0.82.

FibroGen (NASDAQ:FGEN) last posted its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.21. The company had revenue of $46.33 million for the quarter, compared to analyst estimates of $34.00 million. During the same period last year, the business earned ($0.52) earnings per share. As a group, equities analysts anticipate that FibroGen, Inc. will post -0.86 EPS for the current fiscal year.

FibroGen Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.